Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer

Journal of the National Cancer Institute

Volumn 89, Issue 17, 1997, Pages 1293-1299

  Dillner, Joakim ^a,b   Lehtinen, Matti ^b   Björge, Tone ^c,d   Luostarinen, Tapio ^e   Youngman, Linda ^f   Jellum, Egil ^g   Koskela, Pentti ^b   Gislefoss, Randi Elin ^g   Hallmans, Göran ^h   Paavonen, Jorma ⁱ   Sapp, Martin ^j   Schiller, John T ^k   Hakulinen, Timo ^l   Thoresen, Steinar ^d   Hakama, Matti ^m  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d Radium Hospital   (Norway)

^e FINNISH CANCER REGISTRY   (Finland)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g Kreftforeningen   (Norway)

^h UMEÅ UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

^j JOHANNES GUTENBERG UNIVERSITY   (Germany)

^k NATIONAL CANCER INSTITUTE   (United States)

^l KAROLINSKA INSTITUTE   (Sweden)

^m UNIVERSITY OF TAMPERE   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CHLAMYDIA TRACHOMATIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEROCONVERSION; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

EID: 0030760058     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.17.1293     Document Type: Article

References (38)

1. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85: 958-64.
2. Hakama M, Lehtinen M, Knekt P, Aromaa A, Leinikki P, Miettinen A, et al. Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. Am J Epidemiol 1993;137:166-70.
3. Brinton LA, Tashima KT, Lehman HF, Levine RS, Mallin K, Savitz DA, et al. Epidemiology of cervical cancer by cell type. Cancer Res 1987;47: 1706-11.
4. Human papillomaviruses. IARC Monogr Assessment of Carcinog Risk Hum 1995;64.
5. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
6. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
7. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
8. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995;171:1026-30.
9. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494-9.
10. Andersson-Ellstrom A, Dillner J, Hagmar B, Schiller J, Sapp M, Forssman L, et al. Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 1996;23:234-8.
11. Dillner J, Kallings I, Brihmer C, Sikstrom B, Koskela P, Lehtinen M, et al. Seropositivity to human papillomavirus types 16, 18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. J Infect Dis 1996; 173:1394-8.
12. Dillner J. Serology of human papillomavirus. Cancer J 1995;8:264-9.
13. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995;172:1425-30.
14. Dillner J, Wiklund F, Lenner P, Eklund C, Fredriksson-Shanazarian V, Schiller JT, et al. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with cervical cancer. Int J Cancer 1995;60:377-82.
15. Nonnenmacher B, Hubbert NL, Kirnbauer R, Shah KV, Munoz N, Bosch FX, et al. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995;172:19-24.
16. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ 1996;312:537-9.
17. Tuomilehto J, Zimmet P, Mackay IR, Koskela P, Vidgren G, Toivanen L, et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet 1994; 343:1383-5.
18. Jellum E, Andersen A, Lund-Larsen P, Theodorsen L, Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect 1995;103 Suppl 3:85-8.
19. Lenner P, Hallmans G, Weinehall L, Stenling R. Population-based biological specimen bank. New possibilities for epidemiologic cancer research. Lakartidningen (J Swedish Med Assoc) 1991;88:4447-9.
20. Volpers C, Schirmacher P, Streeck RE, Sapp M. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 1994;200:504-12.
21. Heino P, Eklund C, Fredriksson-Shanazarian V, Goldman S, Schiller JT, Dillner J. Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst 1995;87:437-40.
22. Chua K, Wiklund F, Lenner P, Angstrom T, Hallmans G, Bergman F, et al. A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer 1996;68:54-9.
23. Parish S, Collins R, Peto R, Youngman L, Barton J, Jayne K, et al. Cigarette smoking, tar yields, and non-fatal myocardial infarction: 14,000 cases and 32,000 controls in the United Kingdom. The International Studies of Infarct Survival (ISIS) Collaborators. BMJ 1995;311:471-7.
24. Breslow NE, Day NE. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ 1980;32:5-338.
25. Mehta CP, Patel NR, Gray R. Computing exact confidence intervals for the common odds ratio in several 2 × 2 contingency tables. J Am Stat Assoc 1985;80:969-73.
26. EGRET. User's manual. Seattle (WA): Statistics and Epidemiology Research Corporation, 1993.
27. Ponten J, Adami HO, Bergstrom R, Dillner J, Friberg LG, Gustafsson L, et al. Strategies for global control of cervical cancer. Int J Cancer 1995;60: 1-26.
28. von Knebel Doeberitz M, Rittmuller C, Aengeneyndt F, Jansen-Durr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol 1994;68:2811-21.
29. Kjaer SK, de Villiers EM, Caglayan H, Svare E, Haugaard BJ, Engholm G, et al. Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark) - a second look. Br J Cancer 1993;67:830-7.
30. Reeves WC, Gary HE, Johnson PR, Icenogle JP, Brenes MM, deBritton RM, et al. Risk factors for genital papillomavirus infection in populations at high and low risk for cervical cancer. J Infect Dis 1994;170:753-8.
31. Bosch FX, Munoz N, de Sanjose S, Izarzugaza I, Gili M, Viladiu P, et al. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992; 52:750-8.
32. Data from publicly available databases at the Cancer Registry of Norway and at the Reporting System for Infectious Diseases, Norwegian National Public Health Institute, Oslo, Norway.
33. Munoz N, Castellsague X, Bosch FX, Tafur L, de Sanjose S, Aristizabal N, et al. Difficulty in elucidating the male role in cervical cancer in Colombia. a high-risk area for the disease. J Natl Cancer Inst 1996;88:1068-75.
34. Forsgren M, Skoog E, Jeansson S, Olofsson S, Giesecke J. Prevalence of antibodies to herpes simplex virus in pregnant women in Stockholm in 1969, 1983 and 1989: implications for STD epidemiology. Int J STD AIDS 1994;5:113-6.
35. Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol 1978;24:40-69.
36. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's hospital. Lancet 1979;1:33-5.
37. Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by the polymerase chain reaction. Cancer 1996;77:2275-9.
38. Petterson F. Annual report on the results of treatment of gynecological cancer. Int J Gynecol Obstet 1991;365:27-136.